These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 22001895

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
    Seden K, Back D, Khoo S.
    J Antimicrob Chemother; 2010 Jun; 65(6):1079-85. PubMed ID: 20335191
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM, Tanwar S, Dusheiko GM.
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.
    Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH.
    Curr Opin Infect Dis; 2014 Feb; 27(1):36-45. PubMed ID: 24305043
    [Abstract] [Full Text] [Related]

  • 10. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
    Rodríguez-Torres M.
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
    [Abstract] [Full Text] [Related]

  • 11. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New developments in HCV therapy.
    Kronenberger B, Zeuzem S.
    J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
    [Abstract] [Full Text] [Related]

  • 14. Directly acting antivirals against hepatitis C virus.
    Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, Barreiro P.
    J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C.
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [Abstract] [Full Text] [Related]

  • 17. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M.
    MMW Fortschr Med; 2011 Jul 21; 153(29-31):17. PubMed ID: 21830729
    [No Abstract] [Full Text] [Related]

  • 18. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C, Jesudian A, Zeuzem S, Jacobson I.
    Gut; 2012 May 21; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [Abstract] [Full Text] [Related]

  • 19. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C, Rockstroh JK.
    Curr HIV/AIDS Rep; 2015 Sep 21; 12(3):326-35. PubMed ID: 26228050
    [Abstract] [Full Text] [Related]

  • 20. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
    Bublak R.
    MMW Fortschr Med; 2013 Jun 13; 155 Suppl 1():10-1. PubMed ID: 23961643
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.